MARKET

ANTX

Anthem
ANTX
NYSE
Delisted
P/E
P/S
P/B
MARKET CAP
0.0000
0.0444
0.1039
3,905,278,342.53
AN2 Therapeutics Announces Results From Two Studies Evaluating Its Oral CPSF3 Inhibitor, AN2-502998, For The Treatment Of Chronic Chagas Disease; Parasites Eliminated With 28-Day Treatment In 100% Of Nonhuman Primates
Benzinga · 06/04 11:16
AN2 Therapeutics Announces Results From Two Studies Evaluating Oral CPSF3 Inhibitor, AN2-502998, For Treatment Of Chronic Chagas Disease Caused By Infection With Parasite T. Cruzi
Benzinga · 06/04 11:09
AN2 Therapeutics Price Target Announced at $9.00/Share by Leerink Partners
Dow Jones · 05/14 20:45
AN2 Therapeutics Raised to Outperform From Market Perform by Leerink Partners
Dow Jones · 05/14 20:45
Leerink Partners Upgrades AN2 Therapeutics to Outperform, Announces $9 Price Target
Benzinga · 05/14 20:35
AN2 Therapeutics Enters Open Market Sale Agreement With Jefferies Dated April 9, 2026; Co. May Offer And Sell Common Stock Up To $80M Through Jefferies
Benzinga · 04/20 20:40
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 04/17 12:05
AN2 Therapeutics Files Prospectus To Offer And Sell Up To $300M Of Securities
Benzinga · 04/09 21:32
More

Webull offers Anthem stock information, including NYSE: ANTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ANTX stock methods without spending real money on the virtual paper trading platform.